Trial Profile

A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms IZALCO
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

27 Mar 2026 According to a Sanofi media release, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa (isatuximab) for the treatment of patients with multiple myeloma (MM).
24 Jun 2025 The protocol has been amended to addition in treatment arm and size and addition in pharmacokinetic primary endpoints
24 Jun 2025 Planned number of patients changed from 71 to 118.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com